Provided By GlobeNewswire
Last update: Apr 25, 2025
Vancouver, Canada, April 25, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the filing of a new international patent application for a proprietary treatment targeting anorexia, bulimia and other eating disorders.
Read more at globenewswire.comNASDAQ:CMND (8/15/2025, 8:12:46 PM)
1.03
+0.01 (+0.98%)
Find more stocks in the Stock Screener